Core Viewpoint - The company, Chuangyue Huikang, has been actively collaborating with Alibaba and Ant Group since 2018, focusing on cloud computing, mobile payments, AI, and healthcare scenarios to enhance patient experience and develop innovative solutions in the healthcare sector [1][2]. Group 1: Collaboration Details - Since 2018, the company has engaged in a series of business and technical collaborations with Alibaba's Ant Financial and Alibaba Cloud [2]. - The partnerships leverage each party's strengths to create a "future healthcare" model centered on patient experience, integrating technologies such as mobile payments, credit systems, big data, and artificial intelligence [2]. - Recent efforts have focused on developing AI solutions for healthcare, including medical AI solutions, computing integration, and research innovation scenarios [2]. Group 2: Strategic Goals - The collaboration aims to promote mutual benefits and complementary advantages, driving the development of AI solutions tailored for healthcare clients [2]. - The companies are jointly working on market expansion strategies within the healthcare sector [2].

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Chuangyue Huikang (300451), indicating a decline in both revenue and net profit for the first three quarters of 2025 compared to the previous year [2] - As of January 20, 2026, Chuangyue Huikang's stock closed at 5.69 yuan, down 0.7%, with a trading volume of 730,400 hands and a total transaction amount of 415 million yuan [1] - The company reported a main revenue of 862 million yuan for the first three quarters of 2025, a year-on-year decrease of 26.26%, and a net profit attributable to shareholders of -122 million yuan, a decline of 331.69% [2] Group 2 - In the third quarter of 2025, the company's single-quarter main revenue was 285 million yuan, down 35.5% year-on-year, and the net profit attributable to shareholders was -41.67 million yuan, a decrease of 264.2% [2] - The company has shifted its main business focus from product development and sales to a broader range of services, including smart healthcare, internet medical services, medical IoT, and health city solutions [2] - The company's debt ratio stands at 20.27%, with an investment income of 4.44 million yuan and financial expenses of -5.32 million yuan, while maintaining a gross profit margin of 49.87% [2]

证券代码：300451 证券简称：创业慧康 公告编号：2026-001 创业慧康科技股份有限公司 关于筹划控制权变更事项进展的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、本次筹划控制权变更事项的情况 2025 年 11 月 12 日，杭州更好智投管理咨询合伙企业（有限合伙）（以下 简称"杭州更好"或"更好智投"）与创业慧康科技股份有限公司（以下简称"公 司"）第一大股东、持股 5%以上股东葛航先生签署了《股份转让协议》，约定 葛航将通过协议转让的方式向杭州更好转让公司 96,525,096 股股份（约占公司总 股本的 6.23%），每股转让价格为人民币 5.18 元（"协议转让"），不低于公司 前一交易日（2025 年 11 月 7 日）股票收盘价的 80%；同日，杭州更好与葛航先 生签署了《关于创业慧康科技股份有限公司的表决权委托暨一致行动协议》，约 定葛航将持有的公司 155,780,282 股（约占公司总股本的 10.06%，含协议转让对 应的 96,525,096 股股份）股份表决权全权委托给杭州更好行使。上述协议签署后， 杭州更好与葛航形成 ...

Core Viewpoint - The stock of Chuangyue Huikang experienced a decline of 6.33% on January 15, with a trading volume of 1.12 billion yuan, indicating significant market activity and investor sentiment concerns [1]. Financing and Margin Trading - On January 15, Chuangyue Huikang had a financing buy amount of 127 million yuan, with a net financing purchase of 33.88 million yuan after repayments [1]. - The total margin trading balance reached 620 million yuan, with the financing balance accounting for 6.41% of the circulating market value, indicating a high level of leverage compared to the past year [1]. - In terms of securities lending, 5,500 shares were repaid while 900 shares were sold, with a total selling amount of 5,589 yuan, and the remaining securities lending balance was 428,900 shares [1]. Company Overview - Chuangyue Huikang Technology Co., Ltd. is based in Hangzhou, Zhejiang Province, and was established on December 10, 1997, with its IPO on May 14, 2015 [1]. - The company specializes in healthcare information technology, including software applications, system integration, and environmental monitoring services, with revenue contributions of 44.95% from technical services, 44.48% from software sales, and 9.59% from system integration [1]. Financial Performance - For the period from January to September 2025, Chuangyue Huikang reported a revenue of 862 million yuan, a year-on-year decrease of 26.26%, and a net profit attributable to shareholders of -122 million yuan, reflecting a significant decline of 331.69% [2]. - Cumulatively, the company has distributed 230 million yuan in dividends since its A-share listing, with 30.94 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased to 64,400, while the average circulating shares per person increased by 0.70% to 23,711 shares [2]. - Notable changes in institutional holdings include a reduction in shares held by major shareholders, such as Nuoan Active Return Mixed A and Southern CSI 1000 ETF [3].

Core Viewpoint - The company, Chuangye Huikang, is actively developing AI applications in the healthcare sector, focusing on technology research and development, practical implementation, and ecosystem building [2] Group 1: AI Applications - The company has a comprehensive and in-depth layout in the AI medical field, focusing on technology research and development, practical implementation, and ecosystem building [2] - The company has independently developed the BsoftGPT large model service platform and is collaborating with Zhejiang University Computer Research Institute to develop the Qizhen Medical Large Model [2] - The company has launched the "Huikang·Cloud Hub" intelligent agent, which possesses reasoning and planning capabilities [2] Group 2: Practical Implementation - The company empowers over fifty intelligent scenarios, including clinical decision support, intelligent generation of electronic medical records, internet hospitals, nursing management, grassroots public services, medical insurance, and physical examinations [2] - The company has implemented products such as the Smart Medical Assistant (MedCopilot) and AI Key Patient Tracking System (APTS), which are currently being piloted in multiple hospitals [2] Group 3: Ecosystem and Solutions - The company has nearly 30 years of industry experience and has established a complete solution system, forming a core layout that deeply integrates technology and practical scenarios [2]

Core Viewpoint - Shanghai Chuangyi Huikang Technology Co., Ltd. has been established with a registered capital of 30 million yuan, focusing on various technology and service sectors [1] Company Summary - The legal representative of the newly established company is Yao Zhipeng [1] - The company's business scope includes information system integration services, retail of computer software and hardware, big data services, software development, and network and information security software development [1] - Chuangyi Huikang holds 100% ownership of the new company [1]

今日A股股指盘中集体下跌，盘面上，医疗服务、CRO概念、医药商业等板块领涨，商业航天、大 飞机等板块领跌，创业板软件ETF华夏（159256）盘中跌1.85%，持仓股卫宁健康大涨超16%，万兴科 技涨超10%，创业慧康、鼎捷数智、拓尔思等股涨幅居前，航天智装、慧博云通、银之杰等股跌幅居 前。 相关产品：创业板软件ETF华夏（159256）、创业板200ETF华夏（159573）、人工智能AIETF （515070）。 每日经济新闻 消息方面，1月12日，美国顶尖大模型独角兽Anthropic面向医疗保健领域，正式推出新一代模型 Claude Opus 4.5，并同步扩展其在生命科学方向的能力。Anthropic官方提到，该版本重点覆盖事前授 权、理赔申诉、护理协调以及患者消息分类等高频流程，目标是降低人工成本并提升处理效率。同时， 据Anthropic官方公布，Claude目前已接入多项核心医疗行业数据库，进一步强化其在合规与业务流程中 的应用能力。 在AI产业链中，软件行业主要处于中游技术层和下游应用层，扮演着核心技术支撑和应用落地的 关键角色。具体来看，软件行业在中游技术层主要提供AI框架、开发平台和算法 ...

据天眼查APP显示，创业慧康科技股份有限公司成立于1997年12月10日，注册资本154912.4692万人民 币。（数据宝） （文章来源：证券时报网） 数据宝统计，截至11:08，创业慧康成交额13.46亿元，创2025年3月17日以来新高。最新股价上涨 6.33%，换手率13.74%。上一交易日该股全天成交额为13.45亿元。 ...

Group 1 - The core point of the article is the establishment of Silk Road Shukang Technology (Gansu) Co., Ltd., which focuses on multiple AI-related businesses [1] - The company is co-owned by Yunshang Gansu Technology Co., Ltd. and Chuangye Huikang (300451), indicating a collaboration between these entities in the AI sector [1] - The business scope of the new company includes big data services, software development, and various AI application software developments, highlighting its focus on advanced technology solutions [1]

Core Viewpoint - Recently, Silk Road Data Technology (Gansu) Co., Ltd. was established, focusing on big data services, software development, and artificial intelligence applications [1] Company Summary - The legal representative of Silk Road Data Technology is Jiao Xiaodong [1] - The company's business scope includes big data services, software development, artificial intelligence application software development, artificial intelligence theory and algorithm software development, and artificial intelligence public data platforms [1] - The company is jointly held by Cloud Gansu Technology Co., Ltd. and Chuangye Huikang (300451) among others [1]